C -reactive protein (CRP)
3 is a prototypic acute phase protein in humans, and levels increase rapidly from Ͻ1 g/ml to as high as 1 mg/ml 24 -48 h after an acute phase stimulus like inflammation, infection, or tissue damage (1, 2) . CRP is produced primarily in the liver in response to IL-6 with other inflammatory cytokines like IL-1 playing a less prominent role (3) . Therefore, CRP is present at very high concentration when acute inflammation is maximal.
CRP is a member of the pentraxin family of proteins. The pentraxins are characterized by cyclic pentameric or hexameric structure composed of five or six identical subunits (4) . Each protomer contains two bound calcium ions on one face of the pentamer, which are involved in binding to its ligands. Binding sites for complement component C1q and Fc␥R are present on the other face of the molecule.
CRP shares many properties in common with IgG, including the ability to activate the classical complement pathway (5), the capacity to interact with Fc␥R (6, 7) , and the ability to bind to ligands. The interaction of CRP with Fc␥R mediates several functions that are analogous to those of IgG, including cytokine secretion and opsonization of bacteria and altered or exposed selfmolecules on damaged cells (2) .
The ability of CRP to suppress acute inflammation has been well documented in studies using mice transgenic for rabbit CRP developed by Samols and colleagues (8 -10) . Mice express only low levels of CRP (Ͻ5 g/ml) and have been useful in models to test in vivo activities of transgenic or injected CRP. Human and rabbit CRP activate mouse complement and bind to receptors on mouse macrophages. Mice expressing high levels of CRP were protected from lethal shock induced by endotoxin, platelet-activating factor (PAF) or the combination of TNF-␣ and IL-1␤ (9) . These results suggest that CRP may regulate the inflammatory cytokine cascade or the response to it. Transgenic mice expressing high levels of CRP and challenged by intratracheal administration of chemotactic agents also showed decreased pulmonary inflammation compared to mice expressing low levels of CRP (8, 10) . The mechanisms responsible for these effects are not well understood, although a direct inhibitory effect of CRP on neutrophil chemotaxis was proposed (8, 11, 12) . CRP has also been shown to interact with PAF, and inhibition of PAF was proposed to account for its protective effect on PAF-induced shock (13) . We have shown that CRPmediated protection against endotoxin shock requires Fc␥R and is associated with the induction of IL-10 and suppression of IL-12 synthesis (14) . Mosser and colleagues (15, 16) have described similar regulatory effects of immune complexes (IC) on macrophage cytokine responses to LPS and other TLR ligands.
CRP is a pattern recognition molecule that binds ligands on microbes and damaged tissue (1) . The binding of CRP to nuclear Ags, including small nuclear ribonucleoproteins, histones, and chromatin, and to apoptotic and necrotic cells has led to investigations of its role in systemic autoimmunity (17) (18) (19) . The effect of CRP on autoimmune disease has been examined in our laboratory and those of others. We first established that CRP could suppress autoantibodies and prolong survival of autoimmune (NZB ϫ NZW)F 1 female mice (NZB/NZW) treated with chromatin to accelerate disease (20) . This work was extended by studies of Szalai et al. (21) who showed that transgenic NZB/NZW mice expressing human CRP from the human promoter had delayed proteinuria and prolonged survival. The transgenic NZB/NZW mice had decreased glomerular pathology with late IC accumulation in glomeruli and increased mesangial deposits. More recently, we determined that CRP given as a single injection to NZB/NZW mice either before disease onset or during active nephritis could rapidly and markedly decrease proteinuria (22) . Survival of both groups of CRP-treated NZB/NZW mice was extended by 10 -13 wk despite a lack of effect on anti-dsDNA Ab levels. In more recent studies using the more fulminant MRL/lpr model of systemic lupus erythematosus, we observed similar protective effects of CRP (23) . Moreover, in the MRL/lpr model, CRP-treated mice showed a decrease in autoantibody levels to dsDNA and lymphadenopathy as well. IC deposition in glomeruli was not affected by CRP treatment, but there was greatly reduced glomerular as well as tubular and interstitial pathology.
A protective effect of transgenic CRP has also been demonstrated in a T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis (24) . CRP increased IL-10 synthesis in cultures of encephalitogenic T cells and APC. These studies suggested a possible common mechanism responsible for CRPmediated immunomodulation involving the participation of IL-10. We hypothesized that the anti-inflammatory activity of CRP might be essential for its therapeutic effect on lupus nephritis, independent of any effect on the autoimmune response.
To investigate the protective effect of CRP in IC glomerulonephritis separately from the autoimmune response, we used an accelerated nephrotoxic nephritis model (NTN) (22) . NTN is a model of acute glomerular inflammation, which is mediated by IC deposited on the glomerular basement membrane (GBM) (25) . Disease is induced by immunizing animals with heterologous IgG followed by injection of anti-GBM Abs from the heterologous species. Our initial studies in this model suggested a requirement for IL-10 in the protective role of CRP (22) . We now report on the cells and receptors responsible for the protective effect of CRP in NTN. A prominent role for macrophages in the induction and maintenance of suppression is seen. In addition, we determine that the highaffinity receptor for IgG and CRP, Fc␥RI, is required for CRPmediated protection. These studies suggest that CRP binding to Fc␥RI on macrophages may provide a unique mechanism for immunoregulation by a member of the innate immune system.
Materials and Methods
Mice C57BL/6 (B6) mice were from the National Cancer Institute. C3 Ϫ/Ϫ mice and IL-10 Ϫ/Ϫ mice on a B6 background were obtained from The Jackson Laboratory and maintained at the Department of Veterans Affairs Medical Center Animal Facility. IL-10 Ϫ/Ϫ mice were further backcrossed onto B6 mice to 10 generations. Fc␥RI Ϫ/Ϫ mice were developed as previously described and backcrossed onto B6 mice (26) . Female mice at 6 -12 wk of age were used in all experiments. All procedures involving animals were approved by the Institutional Review Board of the Department of Veterans Affairs Medical Center.
Reagents
CRP was purified from human pleural effusion fluid as described previously (27) . All preparations were examined on overloaded SDS-PAGE gels to ensure purity. No additional bands other than the major band at ϳ23 kDa were seen. In addition, the preparations were examined for endotoxin by a quantitative chromogenic Limulus amebocyte lysate assay (BioWhittaker). All preparations used contained Ͻ3 endotoxin units (0.3 ng) of endotoxin per mg of protein. Recombinant CRP (Calbiochem) was dialyzed to remove sodium azide and treated for endotoxin contamination with an ActiClean Etox column (Sterogene Bioseparations) to Ͻ3 endotoxin units of endotoxin per mg of protein.
To prepare anti-GBM Ab, New Zealand White rabbits were immunized with purified mouse glomeruli. The purification of mouse GBM and immunization of rabbits were as described elsewhere (28, 29) . Rabbit IgG and CFA were purchased from Sigma-Aldrich.
Induction of NTN and CRP treatment
Mice were injected i.p. with 0.5 mg of rabbit IgG in CFA. NTN was induced 5 days later (day 0) by injection of rabbit anti-GBM serum i.v. Mice received either a single injection of 100 l of anti-GBM on day 0 or three injections of 100 l of rabbit anti-GBM Ab on days 0, 1, and 2 as indicated in the figure legends. A single s.c. injection of 200 g of human CRP was given for treatment. Control mice were treated with an equal volume of saline. CRP treatment was administered either at the same time as the first anti-GBM injection, or 9 -10 days later, after the mice had developed 5ϩ proteinuria. Proteinuria was measured daily using Albustix (Bayer). Grades of proteinuria are expressed as 0, none; 1ϩ, trace; 2ϩ, 30 mg/dl; 3ϩ, 100 mg/dl; 4ϩ, 300 mg/dl; and 5ϩ, Ͼ2000 mg/dl. Blood urea nitrogen (BUN) was measured using Azostix (Bayer).
Histological studies
Kidneys were removed and fixed for 2 h in Bouin's solution and then transferred to 70% ethanol. They were then embedded in paraffin and 2-m sections were cut and stained with H&E or with periodic acid-Schiff reagent. The sections were examined by one of us (J.A.H.) in a blinded manner and scored for glomerular and other renal changes. Histopathology scores were assigned on a 4-point scale based on the number of glomeruli involved and the severity of the lesions (1, Ͻ10%, minimal; 2, 10 -25%, mild; 3, 25-50%, moderate; and 4, Ͼ50%, marked). The glomerular lesion score was determined by averaging scores for glomerular hypertrophy, protein rich fluid, or basement membrane disruption; fibrin thrombi; necrotic debris; periglomerular fibrosis, crescents, or bridging; and presence of neutrophils (Ͼ2/glomerulus). Thirty glomeruli in each kidney were examined.
To measure the presence of macrophages in the glomeruli, kidneys were fixed in acetone for 10 min at 4°C and then air dried. The slides were washed in PBS and blocked with 10% normal rabbit serum for 30 min. For the staining, a primary rat anti-mouse CD68 mAb (Serotec) was used. Slides were washed and incubated with biotinylated rabbit anti-rat IgG secondary Ab for 30 min and washed. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in PBS for 30 min. The sections were developed with a Vectastain ABC kit with 3,3Ј-diaminobenzidine stain and hematoxylin counterstain. Slides stained with a rat IgG2a isotype control Ab were used as negative controls.
Chemokine and cytokine mRNA measurement in kidneys
NTN was induced and mice were injected s.c. with 200 g of CRP or saline on day 0 (early treatment) or day 10 (late treatment). Mice were killed on days 1 and 3 after early CRP treatment or day 11 after late CRP treatment. One kidney from each mouse analyzed was placed in RNAlater (Ambion). RNA was extracted using RNA-STAT60 (Tel-Test) as described by the manufacturer. The integrity of the RNA was confirmed by agarose gel electrophoresis and fluorescent staining with GelStar (Cambrex). The High Capacity cDNA Archive Kit (Applied Biosystems) was used to make cDNA, and mRNA levels were determined by quantitative RT-PCR (qRT-PCR) using TaqMan Gene Expression assays in the Applied Biosystems 7500 Real-Time PCR System. The RNA was normalized to ribosomal protein 13 and compared with levels in untreated B6 mouse kidney. 
Macrophage depletion
Liposomes containing dichloromethylene bisphosphonate (clodronate) were prepared as previously described (30) . Clodronate was provided by Boehringer Mannheim. Phosphatidylcholine and cholesterol were purchased from Sigma-Aldrich. Mice were injected i.v. with 0.2 ml of clodronate liposomes. We previously documented that this treatment depletes 99% of Kupffer cells and 95% of splenic macrophages (31) . Control liposomes were prepared with PBS in place of clodronate.
Complement depletion
Mice were depleted of complement by treatment with cobra venom factor (CVF, Naja naja kaouthia; Quidel) as previously described (32) . Complement depletion was induced by three i.p. injections of 4 U of CVF at 12-h intervals with the last injection 12 h before injection of anti-GBM. This treatment decreases serum C3 levels to Ͻ10% of normal (32) .
Statistical analysis
Survival curves were plotted by the method of Kaplan and Meier and compared by the log-rank test (Mantel-Haenszel test). This analysis takes into account the time of death as well as the absolute numbers of mice surviving. Other comparisons were made between CRP-treated and salinetreated mice using either the two-tailed Student's t test or the MannWhitney U test for nonparametric data. Graphical and statistical analyses were performed using GraphPad Prism software version 4.0 (GraphPad Software).
Results

CRP treatment prevents and reverses proteinuria in B6 mice with NTN
We previously demonstrated that CRP treatment prevents and reverses NTN in B6 mice (23) . These experiments were repeated here to define the conditions required for the analysis of mechanisms involved in CRP-mediated protection. NTN was induced in B6 mice as described in Materials and Methods using three daily doses of anti-GBM serum on days 0, 1, and 2.
Mice were treated with 200 g of CRP or saline on day 0 (early CRP treatment). Some of the saline-treated mice (n ϭ 6) were injected with 200 g of CRP on day 9 (late CRP treatment). FIGURE 1. CRP treatment prevents and reverses NTN in B6 mice. NTN was induced in B6 mice using three daily doses of anti-GBM serum on days 0, 1, and 2. Mice were treated with 200 g of CRP or saline on day 0 (early CRP). Half of the salinetreated mice were injected with 200 g of CRP on day 9 (late CRP). A, Proteinuria was measured daily using Albustix. B, BUN was measured on day 29 using Azostix. C, Survival of saline and early CRP groups. D, Mice were treated on day 0 with different concentrations of purified human CRP (injected dose in g) or with 200 g of rCRP. Proteinuria values are means Ϯ SEM using Albustix. The scale is 0, none; 1ϩ, trace; 2ϩ, 30 mg/dl; 3ϩ, 100 mg/dl; 4ϩ, 300 mg/ dl; and 5ϩ, Ͼ2000 mg/dl (n ϭ 6 for all groups). Proteinuria was measured daily using Albustix on a 0 -5ϩ scale. The mice that were treated with CRP on day 0 were largely protected from the onset of severe proteinuria for the duration of the experiment, although mild proteinuria developed slowly over time in some mice. Mice that were treated with CRP on day 9 showed a rapid reversal of proteinuria (Fig.  1A) . To measure renal function, BUN was measured on day 29. Both the early and late CRP treatments reduced the level of BUN, which is considered a more reliable measurement of renal function than proteinuria (Fig. 1B) . The survival of mice treated with CRP on day 0 was also significantly improved over salinetreated mice, Fig. 1C . To determine the dose requirements for CRP and to ensure that the effect of treatment was not due to any possible minor contaminant of the purified CRP, rCRP was tested. Mice were treated on day 0 with different concentrations of purified human CRP or with 200 g of rCRP that had been dialyzed and depleted of endotoxin. As seen in Fig. 1D , full protection required 200 g of CRP and rCRP was similarly effective as native purified human CRP in preventing proteinuria.
CRP did not affect the Ab response to rabbit IgG as determined by ELISA on day 6 (data not shown). There were also no reproducible differences between CRP-treated and control mice in IC or C3 deposition in glomeruli. Kidney sections were analyzed for glomerular deposition of rabbit and mouse IgG and mouse C3 by immunofluorescence on days 1, 3, 6, and 11 (data not shown). These results suggest that CRP is primarily affecting the inflammatory response to IC rather than the generation or deposition of these complexes.
Macrophage depletion prevents the protective effect of CRP on NTN
NTN was induced in B6 mice using a single dose of anti-GBM serum on day 0. On day 6, mice were injected with either clodronate or control liposomes using a dose and route designed to deplete splenic macrophages and Kupffer cells (30) . Both groups of mice had a modest and transient decrease in proteinuria that may have been due to either paralysis of macrophages by liposome ingestion or consumption of complement following liposome injection. On day 9, mice were treated with 200 g of CRP or saline. Mice that were treated with control liposomes and then with CRP showed a reversal of proteinuria to baseline levels by day 16 ( Fig.  2A) . If, however, the mice had been treated with clodronate liposomes, subsequent treatment with CRP had no effect on proteinuria. Mice treated with saline on day 9 had no response whether they had been pretreated with clodronate or control liposomes (Fig.  2B) . Thus, in the absence of macrophages, CRP is unable to reverse proteinuria.
In a second experiment (Fig. 3) , the effect of macrophage depletion was tested on mice treated at day 0 with CRP to prevent the onset of NTN. Mice were treated with either 200 g of CRP (Fig.  3A) or saline (Fig. 3B ) on day 0. Mice treated with CRP were completely protected from the onset of proteinuria. The CRPtreated mice were then exposed to clodronate or control liposomes on day 3. Mice that were treated with control liposomes were not affected and remained proteinuria-free. However, clodronate treatment rapidly reversed the effect of CRP and mice uniformly developed high-grade proteinuria. Proteinuria persisted until 6 days following clodronate treatment, at which time the proteinuria dropped to 0, suggesting that the effect of CRP was recalled after the return of macrophages, which is expected on days 5-7 after depletion (Fig. 3A) (33) . NTN was induced in control mice, which were then treated with clodronate or control liposomes on day 3 (Fig. 3B) . Clodronate liposome treatment resulted in decreased proteinuria for the period of macrophage depletion (6 days), indicating that effector macrophages in this disease model are accessible to depletion by i.v. administered clodronate liposomes.
IL-10 is required for CRP-mediated protection in NTN
We have previously demonstrated that CRP fails to provide protection from NTN in IL-10 Ϫ/Ϫ mice (23). These results were repeated and expanded here. NTN was induced as described in Fig.  1 using IL-10 Ϫ/Ϫ mice (Fig. 4) . The IL-10 Ϫ/Ϫ mice had decreased survival as compared with B6 mice due to NTN. CRP treatment given either early or late failed to decrease proteinuria (Fig. 4A) or mortality (Fig. 4B) in IL10 Ϫ/Ϫ mice. Thus, the ability to produce IL-10 is required for CRP-mediated protection.
CRP treatment decreases glomerular pathology and macrophage infiltration in B6, but not in IL-10
Ϫ/Ϫ mice Mice with NTN were killed on day 11 after CRP treatment on day 0 (early) or day 9 (late) and renal pathology was analyzed. Glomerular lesion scores are average glomerular pathology scores determined from H&E sections on a 0 -4ϩ scale. The glomerular lesion scores were markedly decreased in late or early CRP-treated B6 mice as compared to saline-treated NTN mice (Fig. 5A) . Two of six mice in the early CRP-treated group failed to respond and were excluded from analysis. Renal pathology in CRP-treated IL-10 Ϫ/Ϫ mice did not differ significantly from saline-treated mice, suggesting that IL-10 is important for CRP's effect on renal disease (Fig. 5A) . As shown in Figs. 1C and 4B, there was greater mortality in IL-10 Ϫ/Ϫ mice compared with B6 mice and many of the mice died before the analysis on day 11. To confirm the pathology findings using a larger number of IL-10 Ϫ/Ϫ mice, an additional experiment was done in which renal pathology was analyzed on day 7. The glomerular lesion scores were 3.76 Ϯ 0.04 for saline-treated mice and 3.6 Ϯ 0.14 for CRP-treated mice, again showing no effect of CRP treatment. The increased pathology in IL-10 Ϫ/Ϫ mice suggests that endogenous IL-10 may ameliorate renal disease in this model and is consistent with earlier studies showing an important effect of IL-10 in a crescentic glomerulonephritis model (34) . Representative H&E-stained sections are shown from a saline-treated IL-10 Ϫ/Ϫ (Fig. 5C ) and an early CRP-treated IL-10 Ϫ/Ϫ mouse (Fig.  5D ). Both sections show glomerular hypertrophy, cellular infiltration, fibrin thrombi, and basement membrane disruption. The improved histopathology in CRP-treated B6 mice was previously published (22) .
Frozen sections of kidneys were stained for infiltrating macrophages using anti-CD68. The average number of CD68 ϩ cells per glomerulus is shown (Fig. 5B) . The number of CD68 ϩ cells correlated well (r ϭ 0.95) with the glomerular lesion score in salinetreated B6 mice. In the B6 mice, early and late CRP treatment decreased the numbers of macrophages in glomeruli nearly to control levels. In IL-10 Ϫ/Ϫ mice, CRP treatment had no effect on CD68 ϩ cell infiltration of the kidneys (Fig. 5B) .
CRP treatment of Fc␥RI Ϫ/Ϫ mice provides early protection from NTN, but protection is not sustained
NTN was induced in Fc␥RI
Ϫ/Ϫ mice and the mice were treated with CRP in an identical manner to B6 mice. Similar to the control mice, Fc␥RI Ϫ/Ϫ mice initially were protected from proteinuria by CRP. However, this protection was short-lived and proteinuria recurred at days 5-7 and became severe by days 9 and 10 (Figs. 6 and 7A). Thus, CRP is able to protect mice from NTN in an Fc␥RI-independent manner, but only briefly. Long-term protection was dependent on Fc␥RI. If mice were given CRP at day 9, CRP again provided moderate transient protection from proteinuria. Unlike the results in B6 mice, this protection was incomplete and of short duration, indicating an important role of Fc␥RI for long-lasting protection. CRP had no significant effect on the survival of Fc␥RI Ϫ/Ϫ mice (data not shown).
Effect of complement depletion on CRP-mediated protection from NTN in B6 and Fc␥RI Ϫ/Ϫ mice
Although CRP activates the classical complement pathway, this activation differs from IC activation of complement in that it is limited to the early steps of the pathway. CRP binds the regulatory protein factor H, thereby preventing C3 and C5 convertase amplification and preventing generation of C5a and the membrane attack complex (35) . In B6 mice, no effect of CVF was seen and CRP was fully protective, suggesting that the major effect of CRP is not mediated by complement in normal mice (Fig. 7B) . These results were supported by experiments using C3 Ϫ/Ϫ mice. In these mice, early CRP treatment provided full protection from proteinuria and mortality in NTN (Fig. 7C) .
Effect of CRP on chemokine mRNA expression in renal tissue of mice with NTN
As CRP treatment decreased the accumulation of macrophages in NTN, we measured the effect of CRP treatment on IL-1␤ and chemokine production in the kidney. Previous studies have demonstrated the importance of IL-1␤ production by inflammatory macrophages in the induction of chemokine production by intrinsic renal cells, such as tubular epithelial cells (36, 37 ). These locally produced chemokines then induce further cellular infiltration and activation, resulting in renal pathology. NTN was induced in B6 mice with a single injection of anti-GBM. Mice were either treated on day 0 with 200 g of CRP or saline and killed at day 1 or 3, or treated with CRP on day 10 and killed on day 11. The kidneys were removed and mRNA was extracted and analyzed by qRT-PCR for IL-1␤, CCL2, CCL3, and CXCL2. Results are presented as the mRNA expression relative to kidneys from untreated B6 mice. As shown in Fig. 8 , CRP treatment decreased the production of IL-1␤, CCL2, CCL3, and CXCL2 on days 1 and 3 after early CRP treatment. All decreases were significant on day 3. Lesser decreases in chemokine production were seen after late CRP treatment. Since chemokines are produced by tubular epithelial cells in the kidney in response to IL-1␤ stimulation, we also looked at the effect of CRP on IL-1␤ production. As seen in Fig. 8A , IL-1␤ production was decreased at days 1, 3, and 11 following CRP treatment. These results were statistically significant on days 3 and 11, 1 day following late CRP treatment. The rapid down-regulation of IL-1␤ following CRP treatment could account for the decreases in local chemokine production.
CRP treatment affects the cytokine and chemokine profile of cells in the peritoneal cavity of mice with NTN
Because CRP produced decreased changes in renal cytokines and chemokines, it was important to determine whether the effects were restricted to the kidney. Since mice are immunized i.p. with rabbit IgG in CFA for the induction of accelerated NTN, we decided to determine whether peritoneal cell production of cytokines and chemokines induced by CFA were altered by CRP treatment. NTN was induced as described in Fig. 2 , and mice were injected i.p. with 200 g of CRP or saline on day 8. After 8 h, mice were killed and peritoneal cells were collected. The RNA extracted from these cells was used to produce 32 P-labeled cDNA probes that were hybridized to mouse inflammatory cytokines and receptors gene array. Representative array data are shown in Fig. 9A . The results shown in Fig. 9B are expressed as the fold increase or decrease in CRP-treated compared with control mice. CRP treatment decreased the production of IL-1␤ similar to results seen in the kidney. There were also substantial decreases in CC and CXC chemokines and their receptors. However, in contrast to the kidneys, CCL2 mRNA was increased in peritoneal cells from CRPtreated mice. Similar results were seen in peritoneal cells collected 2 h after CRP treatment. These results suggest that there is a systemic effect of CRP on inflammatory chemokines and cytokines. In particular, a marked and rapid decrease in IL-1␤, which is produced primarily by macrophages, was observed in both the kidneys and peritoneal cells following CRP treatment of mice with NTN.
Discussion
NTN is an IC-mediated disease that is initiated by heterologous Abs to GBM deposited in the kidney and is enhanced by innate immune signals (25, 38) . In preliminary studies, we described the marked suppression of proteinuria and glomerular pathology in mice with NTN following CRP treatment (22) . The major findings reported here concern the mechanisms by which CRP modulates renal disease in NTN. We first demonstrate that prior depletion of clodronate-sensitive macrophages completely prevents the suppression of NTN by CRP. Intravenously injected clodronate liposomes specifically eliminate macrophages in the spleen and liver (30) . These findings suggest that macrophages are crucial to the effector phase of CRP-mediated suppression. However, this experiment does not indicate whether the initiator cell is a macrophage or another cell with which CRP may interact directly. In mice in which proteinuria had been suppressed by early CRP treatment, depletion of macrophages by treatment with clodronate liposomes reversed suppression. Disease suppression was restored 6 days later without further CRP treatment, suggesting two possibilities. One possibility is that a suppressed population of monocyte/macrophage precursors exists in another compartment like the bone marrow that are programmed by CRP treatment to become suppressive effector cells as they mature. Another possibility is that an initiator cell is generated that can induce the suppressive phenotype in macrophages regenerated from the bone marrow. The findings are most consistent with the latter possibility as the return of suppression corresponds with the time period when macrophages repopulate the liver and spleen after clodronate liposome treatment (5-7 days).
The role of IL-10 in CRP-mediated immunomodulation was indicated in a previous publication from our laboratory, but effects on pathology and the role of macrophage infiltration or glomerular pathology were uncertain due to the high level of mortality in IL-10 Ϫ/Ϫ mice, which are known to be highly sensitive to NTN. These studies confirmed the requirement for IL-10 in CRP treatment of NTN. IL-10 Ϫ/Ϫ mice developed more pathology and higher mortality than B6 mice. CRP treatment had no measurable effect on proteinuria, BUN, survival, renal pathology, or macrophage infiltration of glomeruli in IL-10 Ϫ/Ϫ mice. CRP has been shown to induce IL-10 in macrophages and IL-10 has been suggested to provide an important role in immunosuppression in the experimental allergic encephalomyelitis model (24) . We have previously shown that CRP increases IL-10 synthesis by bone marrow macrophages stimulated with low doses of LPS and that CRP pretreatment of mice increases serum IL-10 levels following LPS injection (14) . This CRP-mediated enhancement of IL-10 production required the FcR ␥-chain. Similar findings have been reported by Mosser et al. (15, 16) using IC to enhance IL-10 synthesis in macrophages stimulated with LPS. More recently, we repeated the in vivo endotoxin challenge experiments using mice deficient in the ␣-chain of Fc␥RI and confirmed that CRP induction of IL-10 requires Fc␥RI (our unpublished results). Thus, the experiments reported here suggest that one of the main mechanisms by which CRP may regulate inflammation is through IL-10 production. The results further suggest that Fc␥RI may be the receptor responsible for IL-10 production induced by CRP.
The importance of the Fc␥RI/IL-10 pathway is supported by the requirement for Fc␥RI in the suppression of NTN by CRP. The critical requirement for Fc␥RI in the mediation of suppression may be unique to CRP. Enhancement of IL-10 synthesis by IC requires the FcR ␥-chain, but does not require either Fc␥RI or Fc␥RIII (26), indicating either redundant roles or involvement of Fc␥RIV. Other models of suppression of NTN and other IC-mediated diseases by high-dose i.v. Ig (IVIG) in mice have shown a crucial role for the regulatory receptor Fc␥RIIb (39, 40) . More recently, an important role for the activating receptors has been shown in a mouse model of immune thrombocytopenic purpura (ITP) (41) . In this model, it was demonstrated that the initiator cell responding to IVIG was a splenic dendritic cell (DC), that it was present in Fc␥RIIb Ϫ/Ϫ mice, and that these DC could transfer suppression to naive mice with ITP.
CRP activation of the human classical complement pathway through the binding of C1q has been well described (1) , although recent data suggest that CRP may activate complement in the mouse through a C1q-independent pathway (42) . CRP activation of complement is limited to the early steps in the pathway (C1, C4, C2, and C3) with little activation of C5b-C9 (43) . CRP regulates the generation of late inflammatory complement components C5a and the membrane attack complex by recruiting the regulatory protein factor H (35). Our results show that CRP's effect on NTN may involve a contribution of the complement pathway, although it did not provide a dominant role in normal B6 mice. The effect of CVF depletion of complement was only seen in Fc␥RI Ϫ/Ϫ mice, suggesting that interaction with Fc␥RI is the major mechanism by which inflammation is suppressed. The early protection from proteinuria during the first week of the treatment may be related to the early phase of NTN, which is more dependent on complement activation than the later phase, which is dominated by Fc␥R and macrophages.
CRP induced a marked reduction in IL-1␤ and chemokines that are important in attracting macrophages to the kidney in NTN. This decrease in message was seen as early as 1 day after CRP injection but was more evident at day 3. Late injection of CRP was less effective in decreasing chemokine mRNA despite the observed decrease in renal pathology. The decrease in IL-1␤ was most marked at day 3, and this cytokine is known to be an important stimulus to chemokine secretion by tubular epithelial cells (37) . The source of IL-1␤ in this model is reported to be the infiltrating macrophages (36) . Results of chemokine and cytokine expression in the peritoneal cavity suggest that the effect of CRP is rapid and not restricted to the kidney. Marked decreases in the level of IL-1␤ message in the peritoneum 2 and 8 h after injection suggest that CRP may provide systemic immunomodulation based on the down-regulation of this proximal activator of the inflammatory cascade.
Several questions remain unanswered. One is whether the initiator cell involved in CRP-mediated suppression of inflammation is of the monocyte/macrophage lineage or another cell type. Our experiments indicate that the suppressive cell itself is a macrophage that may be eliminated by clodronate liposome treatment. However, it is unclear whether CRP acts directly on the macrophage or whether CRP may induce suppression through lymphocytes, DC, or T cells. It has recently been demonstrated that the initiator cell in IVIG-induced suppression of ITP is of the DC lineage and that this cell requires the presence of a ␥-chain-associated receptor, although the effector cell required expression of the suppressive Fc␥RIIb in the recipient (41) . The possibility that CRP acts through such an initiator cell is being examined currently in our laboratory. Another question raised by these studies is the source and role of IL-10. We did not find evidence by qRT-PCR for IL-10 synthesis by either renal cells or peritoneal cells in CRPtreated mice. This could indicate a very transient induction of IL-10 as has been described for macrophages stimulated with LPS in the presence of IC (44) . Alternatively, IL-10 produced centrally in the liver or spleen may be responsible for the suppression of macrophage cytokine and chemokine expression in the kidney and peritoneal cavity. These questions are currently being addressed by additional studies.
In summary, CRP inhibits NTN, a nonautoimmune IC-mediated glomerulonephritis, supporting previous experiments that showed that inhibition of autoantibody formation is not solely responsible for CRP suppression of nephritis in systemic lupus erythematosus mice. These experiments further implicate an important role for Fc␥RI in CRP-mediated immune modulation. The ability of CRP to regulate ongoing active nephritis suggests that CRP may potentially have a role in the clinical treatment of patients with inflammatory disease.
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